Ins and Outs of Patient Derived Xenograft (PDX): An Important Tool for Preclinical Cancer Drug Discovery
With PDX models becoming more and more popular in preclinical cancer research, it’s prime time to explore the topic. Have you considered using PDX models in your preclinical cancer research? What are the challenges and the advantages? What are the methods? Why use a PDX model over a traditional xenograft model? What is the clinical relevance? What models are available? How do you know if your PDX is really just a mouse tumor? What’s an effective method to link phenotypic characterization data and identity confirmation to better assure reproducibility?
Explore answers to these questions. Learn how PDX models are being used, what challenges others have faced and how these models may have application in your research.
San Diego is a major oncology research center and we have CROs that can advance oncology drug programs from concept all the way through Phase 2 and 3 clinical trials.
Using PDX Models for Preclinical Trials of Oncology Therapeutics: Immuno-oncology and Beyond
Thomas B. Broudy, Ph.D., GM & CSO, Crown Bioscience San Diego
Dr. Tommy Broudy is General Manager and CSO of Crown Bioscience’s translational oncology-focused site in San Diego. Prior to this, Tommy was co-founder and CSO of Molecular Response, a premier oncology CRO whose patient derived xenograft (PDX) services business was acquired by CrownBio in Feb 2015. As CSO of CrownBio San Diego, Tommy is leading the establishment of the world’s largest and most diverse portfolio of fully characterized PDX models to help successfully translate novel anti-cancers into the clinic. Tommy’s team are also focused on stratifying the clinical selection process via strategic design of HuTrials (‘mouse clinical trials’), and development of the next generation of immuno-oncology models.
Onco-HuTM Mice for Immunotherapeutic Drug Discovery
Brian W. Soper, Ph.D., Senior Technical Information Scientist, The Jackson Laboratory
Brian has worked at The Jackson Laboratory for more than 20 years. He conducted research on hematopoietic stem cell biology, bone marrow transplantation, immune tolerance and treatment strategies for a mouse model of human enzyme deficiency. He currently provides scientific consultation services to the research community. Brian’s areas of expertise include mouse models of human type 1 and type 2 diabetes, and research with immunodeficient mice. Brian has extensive knowledge in the immunobiology of mice reconstituted with human hematopoietic cells and tumor bearing humanized mice used in immuno-oncology.
PDX, Tumor Stocks & Cell Line Authentication: The Link Between Legacy Data and Reproducibility
Beth Bauer, DVM, DACLAM, Head of IDEXX BioResearch Genetic and Necropsy Services
Since 2004 Dr. Bauer has worked at IDEXX BioResearch, (formerly known as RADIL) and currently serves as Head of the Genetics and Necropsy Laboratories. Dr. Bauer’s leadership in Cell Line Authentication has been recognized by the Global Biological Standards Institute where she serves in their Leadership Circle as well as serving on the Standards Development Organization for ATCC. Beth is an experienced Geneticist who gained extensive hands-on experience in Mouse Genetics and Colony Management during her tenure as the operations manager of the Mutant Mouse Resource Research Center (MMRRC) in Columbia, Missouri.